

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

J. Peter KLEIN, et al.

Serial No.: 09/544,984

Group Art Unit: 1617

Filed: April 07, 2000

Examiner: Mojdeh Bahar

THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALS AND METHOD FOR USING SAME

THE COMMISSIONER FOR PATENTS AND TRADEMARKS
Washington, DC 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.



No additional fee is required.



Applicant is entitled to small entity status under 37 CFR 1.27



Also attached:

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	22	46	0	\$9.00 =	\$0.00
Independent Claims	9	16	0	\$42.00 =	\$0.00
Multiple claims newly presented					\$0.00
Fee for extension of time					\$200.00
Total of Above Calculations					\$200.00

Please charge my Deposit Account No. 500417 in the amount of \$200.00. An additional copy of this transmittal sheet is submitted herewith.The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 500417, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Cameron K. Weiffenbach
Cameron K. Weiffenbach
Registration No. 44,488600 13th Street, N.W.
Washington, DC 20005-3096
(202)756-8000 CKW:kmb
Facsimile: (202)756-8087
Date: March 11, 2002

Docket No.: 44033-093

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

J. Peter KLEIN, et al.

Application No.: 09/544,984

Filed: April 07, 2000


:
:
:
:
:
:
:

Group Art Unit: 1617

Examiner: Mojdeh Bahar

For: THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALS AND
METHOD FOR USING SAME

AMENDMENT and REQUEST FOR RECONSIDERATION
UNDER 37 CFR § 1.111



Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a response to the non-final Office Action dated October 10, 2001. Please amend the above-identified patent application as set forth below.

AMENDMENT

IN THE CLAIMS:

Please cancel claims 1-7, 16, 17 and 19-46 without prejudice or disclaimer subject to Applicants' right to file divisional applications on the the non-elected invention and non-elected species.

Please amend claim 18 to read as follows:

#10/C
JLP
3/23/02